Stock Price & Analysis

BNGO stock is currently under pressure following the 1-for-60 reverse stock split announcement, which has led to a negative market reaction. It may be prudent to hold the stock until there is more clarity on the company's direction and market sentiment improves.

Price Prediction for BNGO Stock in 2025

Based on the analysis of BNGO's recent reverse stock split announcement and technical indicators, the stock is expected to reach $5.50 by the end of 2025. This prediction considers the potential impact of the 1-for-60 reverse stock split, which could improve market perception and increase the stock price. However, there is also a risk of the stock dropping to $2.50 if the company fails to meet growth expectations. The current price of $3.24 suggests significant volatility and potential for both upside and downside movement.

The S1 support level for BNGO Stock is $2.79 ,The R1 resistant level for BNGO Stock is $3.73.

As of the end of day on 2025-04-02, the price of BNGO Stock was $3.409.

The market cap of BNGO is $11.3M.

BNGO is undervalued based on its low EV/EBITDA and PS ratios, but the stock faces challenges like poor market reaction to its reverse split and high RSI suggesting potential overselling. Exercise caution due to mixed signals.

Bionano Genomics, Inc. is a genomics company, which provides optical genome mapping (OGM) for genome analysis. The Company offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. It markets and sells the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.

BNGO stock could reach $15 by 2030, driven by potential recovery post-reverse stock split and improved fundamentals. The 1-for-60 split aims to boost investor confidence, while recent revenue growth and genetic testing advancements suggest positive momentum.

BNGO has a total of 344 employees.